Mutations in TAP genes are common in cervical carcinomas

Gynecologic Oncology

Volumn 92, Issue 3, 2004, Pages 914-921

  Fowler, Nina L ^a   Frazer, Ian H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cervical cancer; Lesion; TAP genes

Indexed keywords

CARRIER PROTEIN; DNA; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; ISOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSPORT ASSOCIATED PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BLOOD SAMPLING; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CARCINOMA;

EID: 1342343088     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.11.037     Document Type: Article

References (36)

1. Riou G., Favre M., Jeannel D., Bourhis J., Le Doussal V., Orth G. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet. 335:1990;1171-1174.
2. Jochmus-Kudielka I., Schneider A., Braun R., Kimmig R., Koldovsky U., Schneweis K.E.et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. JNCI. 81:1989;1698-1704.
3. Alexander M., Salgaller M.L., Celis E., Sette A., Barnes W.A., Rosenberg S.A.et al. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am. J. Obstet. Gynecol. 175(6):1996;1586-1593.
4. Heemels M.T., Ploegh H. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu. Rev. Biochem. 64:1995;463-491.
5. Carrington M., Colonna M., Spies T., Stephens J.C., Mann D.L. Haplotypic variation of the transporter associated with antigen processing (TAP) genes and their extension of HLA class II region haplotypes. Immunogenetics. 37(4):1993;266-273.
6. Spies T., Bresnahan M., Bahram S., Arnold D., Blanck G., Mellins E.et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature. 348:1990;744-747.
7. Brown M.G., Driscoll J., Monaco J.J. Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature. 353(6342):1991;355-357.
8. Hosken N.A., Bevan M.J. Defective presentation of endogenous antigen by a cell line expressing class I molecules. Science. 248:1990;367-370.
9. Arnold D., Driscoll J., Androlewicz M., Hughes E., Cresswell P., Spies T. Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules. Nature. 360:1992;171-174.
10. Seliger B., Wollscheid U., Momburg F., Blankenstein T., Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 61(3):2001;1095-1099.
11. Wei M.L., Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 356:1992;443-446.
12. Lu J., Wettstein P.J., Higashimoto Y., Appella E., Celis E. TAP-independent presentation of CTL epitopes by Trojan antigens. J. Immunol. 166(12):2001;7063-7071.
13. Alloub M.I., Barr B.B., McLaren K.M., Smith I.W., Bunney M.H., Smart G.E. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ. 298(6667):1989;153-156.
14. Thor S.P., Kirkin A.F., Seremet T., Zeuthen J. Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Int. J. Cancer. 70(5):1997;582-586.
15. Koopman L.A., Mulder A., Corver W.E., Anholts J.D., Giphart M.J., Claas F.H.et al. HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines. Tissue Antigens. 51(6):1998;623-636.
16. Connor M.E., Stern P.L. Loss of MHC class 1 expression in cervical carcinomas. Int. J. Cancer. 46:1990;1029-1034.
17. Cromme F.V., Airey J., Heemels M.-.T., Ploegh H.L., Keating P.J.et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:1994;335-340.
18. Gao X., Jakobsen I.B., Serjeantson S.W. Characterization of the HLA-A polymorphism by locus-specific polymerase chain reaction amplification and oligonucleotide hybridization. Hum. Immunol. 41(4):1994;267-279.
19. Powis S.H., Rosenberg W.M., Hall M., Mockridge I., Tonks S.et al. TAP1 and TAP2 polymorphism in coeliac disease. Immunogenetics. 38(5):1993;345-350.
20. Gostout B.S., Poland G.A., Calhoun E.S., Sohni Y.R., Giuntoli R.L., McGovern R.M.et al. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol. Oncol. 88(3):2003;326-332.
21. Graubert T.A., Ley T.J. How do lymphocytes kill tumor cells? Clin. Cancer Res. 2(5):1996;785-789.
22. Kaklamanis L., Townsend A., Doussis-Anagnostopoulou I.A., Mortensen N., Harris A.L., Gatter K.C. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am. J. Pathol. 145(3):1994;505-509.
23. Hicklin D.J., Kageshita T., Ferrone S. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Tissue Antigens. 48(1):1996;38-46.
24. Kaklamanis L., Leek R., Koukourakis M., Gatter K.C., Harris A.L. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 55(22):1995;5191-5194.
25. Korkolopoulou P., Kaklamanis L., Pezzella F., Harris A.L., Gatter K.C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br. J. Cancer. 73(2):1996;148-153.
26. Fruh K., Ahn K., Peterson P.A. Inhibition of MHC class I antigen presentation by viral proteins. J. Mol. Med. 75(1):1997;18-27.
27. Cromme F.V., Snijders P.J.F., Van den Brule A.J.C., Kenemans P., Meijer C.J.L.M., Walboomers J.M.M. MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression. Oncogene. 8:1993;2969-2975.
28. Ruesch M.N., Laimins L.A. Human papillomavirus oncoproteins alter differentiation-dependent cell cycle exit on suspension in semisolid medium. Virology. 250(1):1998;19-29.
29. Glew S.S., Duggan-Keen M., Ghosh A.K., Ivinson A., Sinnott P., Davidson J.et al. Lack of association of HLA polymorphisms with human papillomavirus-related cervical cancer. Hum. Immunol. 37:1993;157-164.
30. Natali P.G., Nicotra M.R., Bigotti A., Venturo I., Marcenaro L.et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad. Sci. U. S. A. 86(17):1989;6719-6723.
31. Spies T., DeMars R. Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature. 351(6324):1991;323-324.
32. Henderson R.A., Michel H., Sakaguchi K., Shabanowitz J., Appella E.et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science. 255:1992;1264-1268.
33. Smith K.D., Epperson D.F., Lutz C.T. Alloreactive cytotoxic T-lymphocyte-defined HLA-B7 subtypes differ in peptide antigen presentation. Immunogenetics. 43(1-2):1996;27-37.
34. Gabathuler R., Reid G., Kolaitis G., Driscoll J., Jefferies W.A. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J. Exp. Med. 180(4):1994;1415-1425.
35. Harel-Bellan A., Quillet A., Marchiol C., DeMars R., Tursz T., Fradelizi D. Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. Proc. Natl. Acad. Sci. U. S. A. 83(15):1986;5688-5692.
36. Storkus W.J., Howell D.N., Salter R.D., Dawson J.R., Cresswell P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J. Immunol. 138(6):1987;1657-1659.